Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16

被引：0
|
作者：
Jacob P. Thyssen
Marjolein de Bruin-Weller
Antonio Costanzo
Susanne Grond
Christopher Schuster
Chunyuan Liu
Maria Jose Rueda
Yun-Fei Chen
Andreas Pinter
Thomas Bieber
机构：
[1] University of Copenhagen,Department of Dermatology, Bispebjerg Hospital
[2] University Medical Center Utrecht,Department of Dermatology and Allergology, National Expertise Center of Atopic Dermatitis
[3] Humanitas University,Dermatology, Department of Biomedical Sciences
[4] Humanitas Research Hospital,Dermatology
[5] Eli Lilly and Company,Department of Dermatology
[6] Medical University of Vienna,Department of Dermatology, Venereology and Allergology
[7] Tigermed-BDM Inc,Department of Dermatology and Allergy
[8] University Hospital Frankfurt,undefined
[9] University Hospital,undefined
[10] Christine Kühne-Center for Allergy Research and Education (CK-CARE),undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Atopic dermatitis; Classification and regression tree analysis; Severe itch;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3574 / 3587
页数：13
相关论文
共 50 条
  • [1] Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
    Thyssen, Jacob P.
    de Bruin-Weller, Marjolein
    Costanzo, Antonio
    Grond, Susanne
    Schuster, Christopher
    Liu, Chunyuan
    Rueda, Maria Jose
    Chen, Yun-Fei
    Pinter, Andreas
    Bieber, Thomas
    ADVANCES IN THERAPY, 2023, 40 (08) : 3574 - 3587
  • [2] Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch
    Matthias Augustin
    Maddalena Napolitano
    Rosa Izu-Belloso
    C. Elise Kleyn
    Susanne Silvia Sabatino
    Joaquin R. Grond
    Chunyuan Otero-Asman
    Ziad Liu
    Toshifumi Reguiai
    undefined Nomura
    Dermatology and Therapy, 2025, 15 (2) : 437 - 444
  • [3] Efficacy of baricitinib 2-mg stratified by baseline body surface area in adults with moderate-to-severe atopic dermatitis
    Silverberg, Jonathan I.
    Boguniewicz, Mark
    Waibel, Jill
    Weisman, Jamie
    Strowd, Lindsey
    Sun, Luna
    Ding, Yuxin
    Goldblum, Orin
    Nunes, Fabio P.
    Simpson, Eric L.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB128 - AB128
  • [4] Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
    Carrascosa, Jose-Manuel
    Narcisi, Alessandra
    Nomura, Toshifumi
    Staender, Sonja
    Vestergaard, Christian
    Sabatino, Silvia
    Grond, Susanne
    Koppelhus, Uffe
    Elrayes, Mohamed
    Chen, Yun-Fei
    Liu, Chunyuan
    Wollenberg, Andreas
    DERMATOLOGY AND THERAPY, 2024, 14 (06) : 1561 - 1573
  • [5] Baricitinib for the treatment of pediatric patients with moderate-to-severe atopic dermatitis
    Paller, Amy
    Chu, Chia-Yu
    Yang, Chin-Yi
    Janes, Jonathan
    Prakash, Apurva
    Rueda, Maria Jose
    Stanley, Sarah
    Wu, Wen-Shuo
    Zhang, Xin
    Eichenfield, Lawrence
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB108 - AB108
  • [6] Clinical tailoring of baricitinib 2 mg in atopic dermatitis: baseline body surface area and rapid onset of action identifies response at week 16
    Silverberg, J. I.
    Boguniewicz, M.
    Waibel, J.
    Weisman, J.
    Strowd, L.
    Sun, L.
    Ding, Y.
    Goldblum, O.
    Nunes, F. P.
    Simpson, E. L.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E69 - E70
  • [7] Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
    Silverberg, Jonathan, I
    Boguniewicz, Mark
    Waibel, Jill
    Weisman, Jamie
    Strowd, Lindsay
    Sun, Luna
    Ding, Yuxin
    Feely, Meghan
    Nunes, Fabio P.
    Simpson, Eric L.
    DERMATOLOGY AND THERAPY, 2022, 12 (01) : 137 - 148
  • [8] Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
    Jonathan I. Silverberg
    Mark Boguniewicz
    Jill Waibel
    Jamie Weisman
    Lindsay Strowd
    Luna Sun
    Yuxin Ding
    Meghan Feely
    Fabio P. Nunes
    Eric L. Simpson
    Dermatology and Therapy, 2022, 12 : 137 - 148
  • [9] BUDGET IMPACT OF BARICITINIB FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS WITH AN INADEQUATE RESPONSE TO TOPICAL TREATMENTS
    Fenske, C.
    Rosettie, K.
    Ferrufino, C.
    Borns, M.
    Atiya, B.
    Johnson, N.
    Wehler, E.
    VALUE IN HEALTH, 2021, 24 : S229 - S229
  • [10] Disease severity and needs of patients with moderate-to-severe Atopic Dermatitis
    Siegels, D.
    Abraham, S.
    Heinrich, L.
    Birkner, T.
    Haufe, E.
    Weidinger, S.
    Werfel, T.
    Schmitt, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S197 - S197
12345